The estimated Net Worth of Nadav Friedmann is at least $2.6 Milion dollars as of 3 October 2022. Nadav Friedmann owns over 9,376 units of Cassava Sciences Inc stock worth over $2,183,940 and over the last 10 years he sold SAVA stock worth over $0. In addition, he makes $416,972 as Chief Medical and Operating Officer i Director at Cassava Sciences Inc.
Sign up
Nadav Friedmann SAVA stock SEC Form 4 insiders trading
Nadav has made over 3 trades of the Cassava Sciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,376 units of SAVA stock worth $8,907 on 3 October 2022.
The largest trade he's ever made was exercising 28,015 units of Cassava Sciences Inc stock on 17 March 2021 worth over $1,500,203. On average, Nadav trades about 7,267 units every 63 days since 2014. As of 3 October 2022 he still owns at least 79,910 units of Cassava Sciences Inc stock.
You can see the complete history of Nadav Friedmann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nadav Friedmann biography
Dr. Nadav Friedmann M.D., Ph.D. serves as Chief Medical and Operating Officer, Director of the Company. Dr. Friedmann has served as Chief Operating Officer since 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
What is the salary of Nadav Friedmann?
As the Chief Medical and Operating Officer i Director of Cassava Sciences Inc, the total compensation of Nadav Friedmann at Cassava Sciences Inc is $416,972. There are 2 executives at Cassava Sciences Inc getting paid more, with Remi Barbier having the highest compensation of $1,073,230.
How old is Nadav Friedmann?
Nadav Friedmann is 77, he's been the Chief Medical and Operating Officer i Director of Cassava Sciences Inc since 2004. There are 3 older and 6 younger executives at Cassava Sciences Inc. The oldest executive at Cassava Sciences Inc is Sanford Robertson, 88, who is the Independent Director.
What's Nadav Friedmann's mailing address?
Nadav's mailing address filed with the SEC is C/O CASSAVA SCIENCES, INC., 6801 N. CAP OF TX HWY; BLDG. 1 SUITE 300, AUSTIN, TX, 78731.
Insiders trading at Cassava Sciences Inc
Over the last 6 years, insiders at Cassava Sciences Inc have traded over $0 worth of Cassava Sciences Inc stock and bought 1,178,376 units worth $9,853,781 . The most active insiders traders include Sanford Robertson, Richard Barry oraz Patrick J Md Phd Scannon. On average, Cassava Sciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $1,235,207. The most recent stock trade was executed by Sanford Robertson on 26 April 2024, trading 69,000 units of SAVA stock currently worth $1,518,000.
What does Cassava Sciences Inc do?
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
What does Cassava Sciences Inc's logo look like?
Complete history of Nadav Friedmann stock trades at Cassava Sciences Inc
Cassava Sciences Inc executives and stock owners
Cassava Sciences Inc executives and other stock owners filed with the SEC include:
-
Remi Barbier,
Chairman of the Board, President, Chief Executive Officer -
Remi Barbier,
Founder, Chairman, Pres & CEO -
Nadav Friedmann,
Chief Medical and Operating Officer, Director -
Dr. Nadav Friedmann,
Chief Medical Officer & Director -
Eric J. Schoen,
Chief Financial Officer -
Eric Schoen,
Chief Financial Officer -
Sanford Robertson,
Independent Director -
Robert Gussin,
Independent Director -
Patrick Scannon,
Independent Director -
Michael O' Donnell,
Independent Director -
Dr. James W. Kupiec M.D.,
Chief Clinical Devel. Officer -
Dr. Lindsay H. Burns Ph.D.,
Sr. VP of Neuroscience -
Dr. Michael Marsman,
Sr. VP of Regulatory Affairs -
Michael Zamloot,
Sr. VP of Technical Operations -
Dr. George Thornton,
Sr. VP of Technology -
Saira Ramasastry,
Director -
Pierre Gravier,
Director -
Claude Nicaise,
Director -
Robert Christopher Cook,
SVP & General Counsel -
Richard Barry,
Director -
James William Kupiec,
Chief Medical Officer -
Robert Eugene Jr Anderson,
Director